TY - JOUR
T1 - Low-molecular-weight heparin in the management of Trousseau's syndrome
AU - Walsh-McMonagle, Denise
AU - Green, David
N1 - Copyright:
Copyright 2007 Elsevier B.V., All rights reserved.
PY - 1997/8/15
Y1 - 1997/8/15
N2 - BACKGROUND. Thrombophlebitis migrans is a major cause of morbidity in approximately 11% of patients with cancer. Thrombosis may predate the appearance of malignancy, and patients with thrombosis often respond poorly to warfarin. METHODS. Four patients with extensive thrombosis and cancer are described in this article. Enoxaparin, a low-molecular-weight heparin, was administered subcutaneously to these patients for 5, 6, 26, and 27 months, respectively. The literature on the management of Trousseau's syndrome was reviewed and analyzed. RESULTS. All four patients remained free of venous thromboembolism while being treated with low-molecular-weight heparin, acutely and during follow-up. Previously published studies suggest that therapy with low-molecular-weight heparin results in lower mortality than standard heparin therapy. CONCLUSIONS. Further study to evaluate the safety and efficacy of low-molecular-weight heparin for both prophylaxis and treatment of thromboembolism in association with malignancy may lead to decreased morbidity and better quality of life for patients with this disorder.
AB - BACKGROUND. Thrombophlebitis migrans is a major cause of morbidity in approximately 11% of patients with cancer. Thrombosis may predate the appearance of malignancy, and patients with thrombosis often respond poorly to warfarin. METHODS. Four patients with extensive thrombosis and cancer are described in this article. Enoxaparin, a low-molecular-weight heparin, was administered subcutaneously to these patients for 5, 6, 26, and 27 months, respectively. The literature on the management of Trousseau's syndrome was reviewed and analyzed. RESULTS. All four patients remained free of venous thromboembolism while being treated with low-molecular-weight heparin, acutely and during follow-up. Previously published studies suggest that therapy with low-molecular-weight heparin results in lower mortality than standard heparin therapy. CONCLUSIONS. Further study to evaluate the safety and efficacy of low-molecular-weight heparin for both prophylaxis and treatment of thromboembolism in association with malignancy may lead to decreased morbidity and better quality of life for patients with this disorder.
KW - Anticoagulants
KW - Cancer patients
KW - Low-molecular-weight heparin
KW - Thrombosis
UR - http://www.scopus.com/inward/record.url?scp=0030853997&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030853997&partnerID=8YFLogxK
U2 - 10.1002/(SICI)1097-0142(19970815)80:4<649::AID-CNCR1>3.0.CO;2-I
DO - 10.1002/(SICI)1097-0142(19970815)80:4<649::AID-CNCR1>3.0.CO;2-I
M3 - Review article
C2 - 9264346
AN - SCOPUS:0030853997
SN - 0008-543X
VL - 80
SP - 649
EP - 655
JO - cancer
JF - cancer
IS - 4
ER -